
|Videos|October 25, 2016
Results of a First-Line Study of Pembrolizumab in Advanced Urothelial Cancer
Author(s)Arjun Balar, MD
Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the results of a recent first-line study of pembrolizumab in advanced urothelial cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Talquetamab Shows Durable Responses in R/R MM at 3-Year Follow-Up
2
Cost-Effectiveness of Perioperative Pembro in Head and Neck Cancer Hinges on PD-L1 Expression
3
FDA Does Not Approve 177Lu-Edotreotide for GEP-NETs
4
Dr Lonial on Using MRD Negativity to Guide Maintenance Discontinuation in Myeloma
5







































